EXAS Stock Forecast 2025-2026
Distance to EXAS Price Targets
EXAS Price Momentum
10 Quality Stocks Worth Considering Now
Researching Exact Sciences (EXAS) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on EXAS and similar high-potential opportunities.
Latest EXAS Stock Price Targets & Analyst Predictions
Based on our analysis of 31 Wall Street analysts, EXAS has a bullish consensus with a median price target of $69.16 (ranging from $52.00 to $86.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $44.99, the median forecast implies a 53.7% upside. This outlook is supported by 23 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Dan Brennan at TD Cowen, projecting a 91.2% upside. Conversely, the most conservative target is provided by Gerard Cassidy at RBC Capital, suggesting a 15.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EXAS Analyst Ratings
EXAS Price Target Range
Latest EXAS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EXAS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 13, 2025 | RBC Capital | Gerard Cassidy | Sector Perform | Initiates | $52.00 |
| Feb 26, 2025 | Piper Sandler | David Westenberg | Overweight | Maintains | $70.00 |
| Feb 24, 2025 | Scotiabank | Sung Ji Nam | Sector Outperform | Maintains | $73.00 |
| Feb 20, 2025 | Barclays | Luke Sergott | Overweight | Maintains | $65.00 |
| Feb 20, 2025 | B of A Securities | Derik De Bruin | Buy | Maintains | $65.00 |
| Jan 23, 2025 | Barclays | Luke Sergott | Overweight | Initiates | $70.00 |
| Jan 13, 2025 | Benchmark | Bruce Jackson | Buy | Reiterates | $65.00 |
| Dec 13, 2024 | B of A Securities | Derik De Bruin | Buy | Maintains | $72.00 |
| Nov 26, 2024 | BTIG | Mark Massaro | Buy | Maintains | $75.00 |
| Nov 26, 2024 | TD Cowen | Dan Brennan | Buy | Maintains | $86.00 |
| Nov 11, 2024 | Piper Sandler | David Westenberg | Overweight | Maintains | $75.00 |
| Nov 6, 2024 | Benchmark | Bruce Jackson | Buy | Maintains | $65.00 |
| Nov 6, 2024 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $75.00 |
| Nov 6, 2024 | TD Cowen | Dan Brennan | Buy | Maintains | $82.00 |
| Nov 6, 2024 | Stifel | Daniel Arias | Buy | Maintains | $67.00 |
| Nov 6, 2024 | Citigroup | Patrick Donnelly | Buy | Maintains | $75.00 |
| Nov 6, 2024 | BTIG | Mark Massaro | Buy | Maintains | $65.00 |
| Nov 6, 2024 | Baird | Catherine Schulte | Outperform | Maintains | $67.00 |
| Nov 6, 2024 | Craig-Hallum | Alex Nowark | Buy | Maintains | $65.00 |
| Nov 6, 2024 | Jefferies | Brandon Couillard | Buy | Maintains | $85.00 |
Exact Sciences Corp (EXAS) Competitors
The following stocks are similar to Exact Sciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Exact Sciences Corp (EXAS) Financial Data
Exact Sciences Corp has a market capitalization of $8.34B with a P/E ratio of -8.0x. The company generates $2.76B in trailing twelve-month revenue with a -37.3% profit margin.
Revenue growth is +10.3% quarter-over-quarter, while maintaining an operating margin of -4.9% and return on equity of -37.1%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Exact Sciences Corp (EXAS) Business Model
About Exact Sciences Corp
Develops diagnostic tests for cancer detection.
Exact Sciences generates revenue primarily through the sale of its proprietary diagnostic tests, such as Cologuard, which focuses on early detection of colorectal cancer. The company leverages its innovative research and development capabilities to expand its product offerings and enhance patient access to critical health screenings.
Headquartered in Madison, Wisconsin, Exact Sciences significantly impacts patient care and healthcare costs by providing non-invasive testing options. The company's ongoing commitment to innovation positions it as a leader in the medical diagnostics and biotechnology sectors.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
6,900
CEO
Mr. Kevin T. Conroy J.D.
Country
United States
IPO Year
2001
Website
www.exactsciences.comExact Sciences Corp (EXAS) Latest News & Analysis
Exact Sciences presented new data on its Oncotype DX Breast Recurrence Score® test at the St. Gallen Conference, highlighting its utility in pre-surgery testing for breast cancer.
New data on Exact Sciences' Oncotype DX test could enhance its market position in cancer diagnostics, potentially increasing revenue and investor confidence in the company's growth prospects.
Exact Sciences Corp. (NASDAQ: EXAS) has been awarded the 2025 Gallup Exceptional Workplace Award, recognizing its engaged workplace culture for the second consecutive year.
Exact Sciences' consecutive Gallup Exceptional Workplace Award highlights strong employee engagement, potentially leading to improved productivity and innovation, positively impacting financial performance and stock value.
3 Top Cancer Biotechs to Keep An Eye On in 2025
20 days agoInvestors in the cancer sector may want to consider stocks such as Novartis, Exact Sciences, and Monte Rosa for potential investment opportunities.
Interest in cancer stocks like Novartis, Exact Sciences, and Monte Rosa signals potential growth opportunities, reflecting investor confidence in advancements and market demand in oncology.
Exact Sciences Corp. (Nasdaq: EXAS) will participate in the TD Cowen Health Care Conference on March 3, 2025, and the Raymond James Institutional Investors Conference on March 4, 2025. Webcasts available.
Exact Sciences' participation in key conferences signals active engagement with investors and potential for new insights, which may influence stock performance and investor sentiment.
2 Stocks Down 59% and 34% to Buy and Hold
1 month agoWarren Buffett advises investors to be cautious when the market is high and to seek underperforming companies with strong prospects for potential investment opportunities.
Buffett's advice highlights potential buying opportunities in underperforming stocks amid market exuberance, suggesting value investments could yield significant returns.
Exact Sciences reported strong Q4 revenue growth but missed EPS estimates due to an $838M impairment charge. The company has robust demand for Cologuard and a solid cash position of $1.04B, targeting 2025 revenue growth.
Exact Sciences' strong Q4 revenue growth signals solid core business health, but the EPS miss from the impairment charge raises concerns. Future product launches and cash position could drive long-term value.
Frequently Asked Questions About EXAS Stock
What is Exact Sciences Corp's (EXAS) stock forecast for 2025?
Based on our analysis of 31 Wall Street analysts, Exact Sciences Corp (EXAS) has a median price target of $69.16. The highest price target is $86.00 and the lowest is $52.00.
Is EXAS stock a good investment in 2025?
According to current analyst ratings, EXAS has 23 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $44.99. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for EXAS stock?
Wall Street analysts predict EXAS stock could reach $69.16 in the next 12 months. This represents a 53.7% increase from the current price of $44.99. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Exact Sciences Corp's business model?
Exact Sciences generates revenue primarily through the sale of its proprietary diagnostic tests, such as Cologuard, which focuses on early detection of colorectal cancer. The company leverages its innovative research and development capabilities to expand its product offerings and enhance patient access to critical health screenings.
What is the highest forecasted price for EXAS Exact Sciences Corp?
The highest price target for EXAS is $86.00 from Dan Brennan at TD Cowen, which represents a 91.2% increase from the current price of $44.99.
What is the lowest forecasted price for EXAS Exact Sciences Corp?
The lowest price target for EXAS is $52.00 from Gerard Cassidy at RBC Capital, which represents a 15.6% increase from the current price of $44.99.
What is the overall EXAS consensus from analysts for Exact Sciences Corp?
The overall analyst consensus for EXAS is bullish. Out of 31 Wall Street analysts, 23 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $69.16.
How accurate are EXAS stock price projections?
Stock price projections, including those for Exact Sciences Corp, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
